Barsha2

[Barsha’s Story #2] “After I was diagnosed with MS, one piece of advice I was given was, ‘Accept your limitations, Barsha. Be honest with yourself when you cannot do something.’ But how can I honestly accept that I cannot be a good mother to my 2 boys? The loss of balance, the incontinence, the exhaustion… these symptoms are nothing compared with the suffering I feel when my sons plead, ‘Momma, please come outside and play!’

Each relapse makes me question whether I am taking the right drug. I need something that is more effective, before its’ too late. There must be something else I can do to stop my symptoms from getting worse.

Only PRODUCT X has been proven to deliver near-complete suppression of subclinical (MRI) activity with superior clinical outcomes versus high-dose IFN β-1a in two identical 2-year trials. Across both trials, PRODUCT X…  Demonstrated near-complete suppression of T1 Gd+ lesions  Reduced relapse rates by nearly half and the risk of disability progression by 40% Should helping Barsha include a switch to a higher-efficacy therapy? Because of past experiences with other high efficacy therapies, are you uncomfortable with this idea?

Now, think about this—PRODUCT X demonstrated a favourable safety profile that allows you to intervene earlier in the course of disease. It is also dosed every 6 months with no routine JCV, cardiovascular or lymphocyte testing.

With the efficacy and favourable safety of PRODUCT X, how could switching Barsha to a more effective therapy be a bad decision?

For Barsha and her family, start PRODUCT X now.